Provectus secure Indian patent for novel Oncology compound PV-10

Provectus Pharmaceuticals, Inc. had received a patent in India protecting its lead oncology agent, PV-10, along with a number of related agents. The patent covers injectable and other forms of the drugs, including capsules, tablets, and oral suspensions and solutions. A range of active compounds are protected, each related to the active ingredient in PV-10."Obtaining patent protection in India for PV-10 and our additional pipeline products is a major milestone, assuring a viable route to access a market representing roughly one-fifth of the world's population," noted Craig Dees, Ph.D., CEO of Provectus. "Additionally, as the Indian pharmaceutical industry becomes a larger player in the worldwide market, this protection establishes an important right of ownership for products sold or made in India."